MetaCap

Alcon (ALC) vs STAAR Surgical (STAA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alcon (ALC) has outperformed STAAR Surgical (STAA) over the past year, losing 3.0% versus a loss of 13.5%. Over five years, ALC leads with a -4.6% price change compared with -75.1% for STAA. Alcon is the larger company by market cap ($35.70 billion vs $1.22 billion), about 29.4 times the size.

On valuation, Alcon trades at a lower forward P/E (19.1x vs 21.4x for STAAR Surgical). Alcon pays a dividend yielding 0.48%, while STAAR Surgical does not currently pay one. Alcon converts more of its revenue into profit, with a net margin of 9.4% versus -33.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALC-3.00%STAA-13.50%
+22%-12%-46%
Nov 21, 20251 yearNov 20, 2026
ALC-9.84%STAA-77.99%
+26%-33%-91%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALC versus STAA key metrics
MetricALCSTAA
Share price$74.31$24.22
Market cap$35.70B$1.22B
1-day change-0.26%-3.24%
YTD return-5.71%+4.89%
1-year return-3.00%-13.50%
5-year return-4.62%-75.08%
P/E ratio (TTM)54.24—
Forward P/E19.0521.39
EPS (TTM)$1.37$0.01
Dividend yield0.48%0.00%
Annual dividend$0.353$0.00
Revenue (latest FY)$10.40B$239.44M
Revenue growth (YoY)+4.94%-23.72%
Net income (latest FY)$980.00M$-80.45M
Gross margin55.24%76.19%
Operating margin13.08%-38.30%
Net margin9.42%-33.60%
52-week high$87.64$35.87
52-week low$61.84$15.59
Distance from 52-week high-15.21%-32.48%
Analyst consensusbuybuy
Avg. price target upside+9.37%+17.92%
Average volume2.01M835.89K
Shares outstanding480.40M50.20M
Employees25,000921
SectorHealth CareHealth Care
IndustryOphthalmic GoodsOphthalmic Goods

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Alcon is about 29.4 times larger than STAAR Surgical by market value ($35.70B vs $1.22B).
  • ALC has outperformed STAA by 10.5 percentage points over the past year.
  • Alcon is more profitable, keeping 9.4 cents of every revenue dollar as net income versus -33.6 cents for STAAR Surgical.
  • Alcon grew revenue faster in its latest fiscal year (+4.94% vs -23.72%).

About Alcon

ALC stock →

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide.

Health Care · Ophthalmic Goods · 25,000 employees

About STAAR Surgical

STAA stock →

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.

Health Care · Ophthalmic Goods · 921 employees

ALC vs STAA FAQ

Which is bigger, Alcon or STAAR Surgical?

Alcon (ALC) is larger, with a market capitalization of $35.70B compared with $1.22B for STAAR Surgical (STAA).

Which stock has performed better over the past year, ALC or STAA?

ALC returned -3.00% over the past 12 months, compared with -13.50% for STAA (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Alcon or STAAR Surgical?

Alcon pays a dividend yielding 0.48%, while STAAR Surgical does not currently pay a regular dividend.

Are Alcon and STAAR Surgical in the same industry?

Yes. Both are classified in the Ophthalmic Goods industry within the Health Care sector.

More comparisons